Define Carcinoma of the Oesophagus. Describe its types, clinical features and management.

The Concept — Two Cancers in One Organ

Oesophageal carcinoma is really two different diseases that share an organ, and grasping this distinction organises the whole topic. The two histological types — squamous cell carcinoma and adenocarcinoma — differ in their site, their risk factors and their epidemiology. Both share a grim feature, however: because the oesophagus has no serosal covering and a rich submucosal lymphatic network, the tumour spreads early and presents late, so the prognosis is generally poor.

The Two Types

The key link to remember is that adenocarcinoma arises from Barrett's oesophagus — the metaplastic change caused by chronic acid reflux — which is why long-standing GORD is a cancer risk.

Clinical Features

The cardinal symptom is progressive dysphagia — difficulty swallowing that begins with solids and advances to liquids as the lumen narrows — accompanied by marked weight loss. Other features include odynophagia (painful swallowing), regurgitation, and anaemia from chronic bleeding. Late or advanced disease may cause hoarseness (recurrent laryngeal nerve involvement), a cough on swallowing (a tracheo-oesophageal fistula), and supraclavicular lymphadenopathy.

Spread

• The routes of spread explain the late, incurable presentation.
• Direct spread invades the mediastinum, trachea and aorta (unchecked by any serosa).
• Lymphatic spread is early and extensive through the submucosal plexus, producing 'skip lesions' away from the main tumour.
• Blood-borne spread reaches the liver and lungs, and transcoelomic spread can occur for lower tumours.

Investigation & Staging

Upper GI endoscopy with biopsy is the diagnostic test, directly visualising the tumour and providing tissue. Staging then determines whether cure is possible: CT of the chest and abdomen (distant spread), endoscopic ultrasound (EUS) (the depth of invasion, T stage, and local nodes, N stage), pet-CT (occult metastases), and staging laparoscopy for lower/junctional tumours (peritoneal disease).

Management

• Curative treatment — possible only in early, localised disease: oesophagectomy (e.g. The Ivor-Lewis or transhiatal approach), usually preceded by neoadjuvant chemotherapy or chemoradiotherapy to improve outcomes.
• Palliative treatment — for the majority who present late, the goal is to relieve dysphagia and maintain quality of life with a self-expanding metal stent, radiotherapy or chemotherapy, laser recanalisation, and nutritional and supportive care.

Nutrition & the Multidisciplinary Approach

Because dysphagia and cachexia dominate the illness, nutritional support is central — many patients need feeding via a fine-bore nasogastric tube, a feeding jejunostomy, or a stent to restore swallowing before and during treatment. Care is delivered by a multidisciplinary team (upper-GI surgeon, oncologist, radiologist, pathologist, dietitian and specialist nurse) that decides between curative and palliative pathways based on stage and fitness. Given that most patients present with incurable disease, honest discussion of prognosis and early involvement of palliative care are as important as the technical options.

Alarm Features & Early Detection

The lesson from the poor prognosis is the value of acting on 'alarm' symptoms: any patient over ~55 with new dysphagia, weight loss, persistent vomiting, gastrointestinal bleeding or iron-deficiency anaemia needs urgent endoscopy. In patients with long-standing reflux, recognising and surveilling Barrett's oesophagus offers the chance to detect adenocarcinoma at a curable, early stage — the main opportunity to improve on the generally dismal outcomes of established disease.

A Note on Palliation

Since most patients are incurable, effective palliation is a large part of oesophageal cancer care. The dominant problem is dysphagia, best relieved by a self-expanding metal stent placed endoscopically, which restores swallowing quickly; radiotherapy (external beam or brachytherapy) and chemotherapy shrink the tumour and prolong relief, and laser or argon-plasma coagulation can recanalise an obstructing tumour. Managing pain, nutrition, and a distressing tracheo-oesophageal fistula (with a covered stent) are central goals, delivered with early palliative-care involvement.

• Diagnostic test = upper GI endoscopy + biopsy; stage with CT, EUS, pet-CT ± staging laparoscopy.
• Curative option = oesophagectomy (± neoadjuvant chemo/chemoradiotherapy) in localised disease only.
• Adenocarcinoma arises from Barrett's oesophagus (chronic GORD).

Site predicts the histological type and the risk factor.

• Two types: squamous (upper/mid third; smoking, alcohol, achalasia) and adenocarcinoma (lower third/GOJ; from Barrett's/GORD, obesity).
• No serosa + rich submucosal lymphatics → early spread, late presentation, poor prognosis.
• Progressive dysphagia (solids→liquids) + weight loss ± hoarseness/cough (fistula)/anaemia.
• Diagnose by endoscopy + biopsy; stage with CT, EUS (T/N), pet-CT, staging laparoscopy.
• Curative: oesophagectomy ± neoadjuvant therapy (early disease only); most get palliation (stent, chemo/radiotherapy).